Fig. 3.

Time-course of serum soluble gp130 (sgp130) concentrations in patients with inflammatory bowel disease. Four patients (a–d) were sampled serially over intervals where their disease status changed from active to inactive. (a) A 32-year-old man with ulcerative colitis who had total colonic involvement treated by sulphasalazine. (b) A 67-year-old man with ulcerative colitis who had left colonic involvement treated by 5-aminosalicylates and prednisolone. (c) A 27-year-old man with Crohn's disease who had colonic involvement treated by sulphasalazine. (d) A 44-year-old man with Crohn's disease who had colonic involvement treated by 5-aminosalicylates and prednisolone. SASP, sulphasalazine; 5ASA, 5-aminosalicylates; PSL, prednisolone; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.